There is an increased need for PrEP uptake among transgender women, men who have sex with men, and transgender women of color in the United States.
Replacing efavirenz (EFV) with raltegravir (RAL) in antiretroviral therapy (ART) may decrease hepatotoxicity in patients who are coinfected with HIV and hepatitis C virus (HCV).
Cytomegalovirus (CMV) viremia is suppressed after the start of antiretroviral treatment (ART) without specific anti-CMV treatment.
Two-drug regimens are shown to be comparable with 3-drug regimens as viable clinical treatment options for HIV.
Particular antiretroviral therapy (ART) regimens may decrease bone mass density (BMD) in both adolescents and older people living with HIV (PWHIV).
Dolutegravir (DTG) discontinuation due to neuropsychologic side effects (NPS) may be associated with pre-existing psychiatric conditions of depression and anxiety.
A long-acting therapy may be noninferior to the current daily oral antiretroviral therapy (ART) in maintaining viral suppression in the treatment of HIV-1 infection.
Dried blood spot viral load may be more accurate and useful than plasma viral load for patients with HIV in settings with limited resources.
Buprenorphine treatments for opioid use disorder among people living with HIV demonstrated beneficial effects in terms of viral load.
The occurrence of cardiac events in a cohort of patients with HIV was significantly higher in patients treated with tenofovir-alafenamide.
Active infection with tuberculosis enhances anti-HIV-1 antibody response.
Combination sofosbuvir/velpatasvir treatment can be highly efficacious in treating hepatitis C virus (HCV) infection in patients coinfected with HIV.
Research results revealed increased risks for cardiovascular disease and insulin resistance among young individuals with HIV.
The point-of-care Dual Path Platform (DPP®) assay may be an inexpensive tool for the diagnosis of neurosyphilis.
Patients with HIV and those with a history of intravenous drug use may have significantly higher rates of hepatic steatosis, according to research results presented at the virtual Conference on Retroviruses and Opportunistic Infections, held from March 8 to 11, 2020. Two groups of researchers examined the role of hepatic steatosis across these patient populations.…
A British man, known as the London patient, may be the second person to be cured of HIV.
The transmission of direct-acting antiviral (DAA) resistance-associated substitutions (RAS) may inhibit hepatitis C virus (HCV) cure rates and elimination efforts.
A child with intrauterine-acquired HIV who received antiretroviral therapy (ART) at 33 hours after birth through age 13 months showed persistent undetectable HIV viremia more than 3 years after discontinuing ART.
Telmisartan did not affect biomarkers of central nervous system inflammation or injury when used as an adjunct to ART for acute HIV infection.
Effective 2-drug regimens may potentially decrease long-term exposure and toxicity with HIV-1 antiretroviral therapy.